drugset / Trial / NCT05004831
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
NaSingle-groupOpen-labelTreatment
Summary
This phase II study aims to explore the efficacy and safety of fruquintinib combined with TAS-102 in the third-line treatment of patients with advanced metastatic colorectal cancer.
Timeline
- Start
- 2022-03-11
- Primary completion
- 2023-09
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Subject | TAS-102 | Small molecule | 70 mg/m2 | Oral |